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Abstract 
Familial amyloid polyneuropathy (FAP) is a most often length-dependent axonal neuropathy, often part of a 
multisystem disorder also affecting other organs, such as cardiac, gastrointestinal, genitourinary, renal, 
meningeal and eye tissue. It is most frequently the result of a mutation in the TTR gene, most commonly a 
p.Val50Met mutation. TTR-FAP is a rare autosomal dominant heritable disabling, heterogeneous disease in 
which early diagnosis is of pivotal importance when attempting treatment. This paper discusses the course of 
four Belgian FAP patients with different TTR mutations  (p.Val48Met; p.Val52Ala; p.Ala59Val; p.Val50Met). 
We also review the diagnosis and differential diagnosis of TTR-FAP, diagnostic studies, follow-up, its current 
treatment and those in development, prognosis and the importance of genetic counselling. At first TTR-FAP is 
often misdiagnosed as a chronic inflammatory demyelinating polyneuropathy or chronic idiopathic axonal 
polyneuropathy. Genetic testing is obligatory to confirm the diagnosis of TTR-FAP, except in familial cases. 
Biopsy samples are an asset in diagnosing TTR-FAP but can be falsely negative. At the moment, tafamidis 
meglumine is considered as first-line treatment in stage I neurological disease. Patients eligible for liver 
transplantation should be carefully selected when first-line therapy fails. 
 
Key words: transthyretin familial amyloid polyneuropathy; liver transplantation; tafamidis meglumine; genetic 
testing.  
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Introduction 
Familial amyloid polyneuropathies (FAPs) are a group of acquired or hereditary, autosomal dominant disorders 
that affect several organs. Three main types are distinguished, dependent on the precursor protein of amyloid: 
transthyretin (TTR), being the most prevalent type, gelsolin and apolipoprotein A-1. TTR, a homotetrameric 
protein, is mainly produced in the liver, whereas a small amount is produced by the choroid plexus and retinal 
cells. Pathogenic mutations induce the dissociation of the tetramer. Subsequent extracellular release of the 
monomers causes them to self-aggregate and ultimately create insoluble amyloid fibrils which precipitate in 
multiple tissues. The most frequent mutation is the p.Val50Met mutation, formerly known as Val30Met [1,2].  
 
Clinical presentation  
The main clinical feature of TTR-FAP is a length-dependent sensorimotor polyneuropathy which often precedes 
marked autonomic dysfunction. The polyneuropathy starts in the feet with loss of temperature and pain 
sensation, or neuropathic pain. It extends progressively above the ankles with involvement of light touch distally 
but dissociated sensory loss proximally. Motor deficits also start in the feet and follow a length-dependent 
pattern. The sensory deficit progresses to the fingers, forearms and eventually the trunk. There are three stages of 
TTR-FAP. In stage I, the disease is limited to the lower limbs with slight weakness of the extensor hallucis 
muscles. In stage II, the hand muscles become wasted and weak. In stage III, the patient is bedridden or confined 
to a wheelchair [3]. Less frequently the pattern is not length-dependent but focal, resulting from amyloid 
deposits. Carpal tunnel syndrome, for example, results from endoneurial amyloid deposition in the median nerve. 
Autonomic dysfunction is often prominent and mostly impairs cardio-circulatory, genitourinary and 
gastrointestinal systems leading to cardiac conduction failure, orthostatic hypotension, erectile dysfunction, 
cachexia, gastroparesis, postprandial diarrhoea or constipation. Eye involvement manifestations include vitreous 
opacities with progressive visual loss, chronic open-angle glaucoma due to trabecular obstruction, and scalloped 
pupils. Progressive renal failure may occur [1]. Familial amyloid cardiomyopathy (FAC) occurs when the 
mutated TTR precipitates in cardiac tissue. FAC should be distinguished from age-related or senile systemic 
amyloidosis in which misaggregation and subsequent precipitation of wild-type TTR leads to wild-type TTR-
related amyloid cardiomyopathy. This heart disease is slowly progressive and clinically well tolerated until 
marked conduction disease, ventricular wall thickening and profound diastolic dysfunction occur  [4].  
Age of onset for early-onset FAP varies between the third to fourth decade. For late-onset FAP, it may vary 
between the sixth and eighth decade. It is endemic in Portugal, Sweden and Japan and shows a merely sporadic 
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presentation worldwide. Death occurs within ten years on average [1,5]. Table 1 shows the main differences 
between early- and late-onset Val50Met TTR-FAP [3]. 
TTR-FAP is a clinically heterogeneous disorder. The factors which influence its phenotype remain unclear. In 
non-Val50Met mutations, for example, cardiomyopathy seems to be more common among men with a late onset 
compared to women with a late onset [1,6]. 
 
Auxiliary investigations 
Electromyography  
EMG may initially be normal in cases of small-fibre polyneuropathy. In an advanced stage of the disease, large 
fibres are also affected, showing a length-dependent axonal sensorimotor polyneuropathy. Demyelinating 
features are less common but may lead to confusion with chronic inflammatory demyelinating polyneuropathy 
[3]. 
Cerebrospinal Fluid  
Although usually normal, CSF protein content may be raised in TTR-FAP. TTR itself is predominantly produced 
in the liver but production in the choroid plexus also occurs. This results in the presence of TTR protein in CSF, 
sometimes leading to meningeal amyloid deposition [1,7]. 
Histology 
Biopsy samples can be taken from (sural) nerve tissue, heart, muscle, kidney, gastrointestinal tract, the labial 
salivary gland and, most commonly, subcutaneous abdominal fat [3,4]. Extracellular amyloid deposits are 
visualized using Congo red staining. The amyloid deposits display a characteristic apple-green birefringence 
under polarised light examination. Additional immunohistochemical stains to identify amyloid protein 
components are mandatory. A negative biopsy, however, does not rule out amyloidosis [1,6,8]. Although the 
amyloid nature can be demonstrated with staining, the amyloid sub-type has to be proven using mass-
spectroscopy-based proteomic analysis or immunohistochemistry [1,5]. A high index of suspicion and an 
experienced pathologist are needed for a correct diagnosis. 
Neural amyloid deposits are mostly found in the endoneurium and endoneurial capillaries in an asymmetric 
manner between and in the fascicles. The destruction of unmyelinated fibres may be visualised early on electron 
microscopy, as well as vanishing of the Schwann cell basal lamina following contact with the amyloid deposits, 
rendering unmyelinated vessels dystrophic [1].   
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MR Neurography (MRN) 
A recent study has provided class III evidence that MRN accurately identifies asymptomatic mutated TTR 
carriers [9]. 
Genetic testing 
The TTR gene is located on chromosome 18q11.2-12. It contains four exons. One hundred nineteen mutations in 
the TTR gene have been reported, all of which are missense point mutations except for one microdeletion. One 
hundred thirteen mutations are amyloidogenic. The p.Val50Met point mutation is by far the most frequent 
mutation in endemic areas. DNA testing is mandatory for the diagnosis, except when typical symptoms manifest 
in cases with a known family history of TTR-FAP [1].  
 
Own cases 
We report four cases of TTR-FAP. Three have rare non-Val50Met TTR mutations. Table 2 shows a summary of 
the main features of these four patients. 
 
Case one concerns a male with a p.Val48Met TTR mutation who deceased at the age of 64 years. This patient 
was initially diagnosed as chronic inflammatory demyelinating polyneuropathy (CIDP) in 1998 based on a 
sporadic chronic sensorimotor polyneuropathy with areflexia, combined axonal and demyelinating features on 
EMG, and a markedly elevated protein content in CSF. Several treatment attempts (plasmapheresis, 
administration of IV immunoglobulins, oral methylprednisolone, oral cyclophosphamide and the anti-CD20-
monoclonal antibody rituximab) were of no avail. Early in his disease course, a sural nerve biopsy had been read 
as mixed axonal and demyelinating, with reportedly negative findings after Congo red staining. Multiple 
autonomic denervation symptoms developed and dramatically evolved along with marked weight loss. In 
January 2012 no amyloidosis was withheld on a rectal and abdominal fat tissue biopsy. Cardiac and ocular 
amyloidosis involvement were excluded. Genetic testing revealed a p.Val48Met (c.142G>A) TTR mutation 
which led to the final diagnosis of TTR-FAP. By the time of the correct diagnosis, the patient was confined to a 
wheelchair, suffered from extreme muscle wasting and severe autonomic symptoms such as severe orthostatic 
hypotension, erectile dysfunction and intestinal motility disorders with profound cachexia. He also suffered from 
a secondary depression. No etiological treatment could be given, resulting in death due to severe autonomic 
failure in 2012. 
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Case two concerns a male with a p.Val52Ala TTR mutation who deceased at the age of 44 years. Symptoms 
started at the age of 40 years with distal leg neuropathic pain, cachexia, gastrointestinal dysmotility, erectile 
dysfunction and an axonal sensory more than motor neuropathy on EMG, raising suspicion of TTR-FAP.   
Prompt genetic testing confirmed the diagnosis later that year revealing a p.Val52Ala (c.155T>C) TTR mutation. 
Family history was negative. Extensive cardiac evaluation was normal. Tafamidis was administered, and the 
patient was stable until orthotopic liver transplantation was performed eleven months later. Several bile duct 
strictures occurred during follow-up, resulting in multiple hospitalizations. Although liver transplantation was 
judged as successful, autonomic denervation progressed rapidly with severe orthostatic hypotension, cachexia 
and anorexia. Tafamidis was no longer accepted for reimbursement post-liver transplantation. Diflunisal was 
used without apparent benefit for 8 months prior to his sudden death in 2016. 
 
Case three is a 43-year-old male with a p.Ala59Val TTR mutation. Symptom onset occurred in 2014. Initial 
complaints at age 41 included distal lower limb neuropathic pain, gastrointestinal dysmotility, erectile 
dysfunction, unexplained orthostatic syncope and rapid weight loss. A cardiac hypertrophy of unknown cause 
was observed two years earlier. EMG showed a mild length-dependent distal lower limb symmetric sensorimotor 
axonal neuropathy. Diagnosis of TTR-FAP was based on prompt genetic testing which showed the p.Ala59Val 
(c.176A>T) TTR mutation. His father and paternal uncle had deceased due to a cardiac disorder of unknown 
etiology. Genetic analysis of his asymptomatic paternal cousin showed the same mutation. Cardiac evaluation 
demonstrated left ventricular hypertrophy with on the ECG a QS-pattern in the anterior leads – compatible with a 
pseudo-infarct appearance as the anterior segments were still contractile – suggesting an infiltrative 
cardiomyopathy. Endomyocardial biopsy confirmed TTR-immunoreactive amyloid deposition. In June 2016, a 
pacemaker was implanted following a severe syncope and documentation of a high grade AV-block. Tafamidis 
therapy started in 2015 and is continued. The patient was initially stable, then had improved general and 
neurologic condition with weight gain and improved exercise capability. After 2 years, orthostatic hypotension 
remains the main symptomatic problem. Cardiac function is stable. Combined heart and liver transplantation was 
considered but withheld as the clinical condition was generally improved.  
 
Case four concerns a 72-year-old male with a p.val50Met TTR mutation. Symptom onset occurred at the age of 
70 years with neuropathic pain and autonomic denervation signs in the feet, and intrinsic foot muscle atrophy 
and weakness, mild bilateral foot drop, sensory ataxia and lower limb areflexia. EMG showed a severe length-
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dependent distal symmetric sensorimotor axonal neuropathy. Until genetic testing confirmed TTR-FAP 
diagnosis, the patient was diagnosed with chronic idiopathic axonal polyneuropathy. No evidence for cardiac 
impairment was withheld. Two of his children show the same mutation after DNA testing, one of which 
experiences a minimal sensory neuropathy. The patient is currently stable under treatment with tafamidis, 
symptomatic neuropathic pain treatment and physiotherapy. He refuses liver transplantation but is not eligible 
anyway according to current liver transplantation criteria. 
 
Discussion 
Diagnosis and differential diagnosis 
In the presence of a positive family history, sensorimotor and autonomic polyneuropathy should raise suspicion 
of TTR-FAP. In the absence of a positive family history, a length-dependent axonal polyneuropathy 
predominantly affecting pain and temperature sensation may indicate TTR-FAP, especially when combined with 
cardiac involvement, prominent autonomic denervation signs and cachexia [1,5]. There is an average of one to 
four years between the onset of first symptoms and diagnosis [1,5]. To confirm amyloidosis, amyloid deposition 
has to be demonstrated on biopsied tissues and DNA testing should be performed [1,5]. Another possible cause 
of amyloidosis is light-chain amyloidosis because of its high incidence in the elderly population. Assessment for 
serum and urinary free lambda and kappa light chains should be performed [3,4]. 
CIDP is the most frequent misdiagnosis. CSF protein content can be raised and nerve conduction velocity may 
be decreased in FAP, although axonal involvement is most common. The differential diagnosis includes the 
following disorders: idiopathic axonal polyneuropathy, lumbar spinal stenosis, diabetic polyneuropathy, chronic 
alcoholism, Charcot-Marie-Tooth neuropathy, motor neuron disease and paraneoplastic syndrome [1,6].    
Therapy 
Targeted therapy 
Next to symptomatic therapy, targeted therapy should be started as soon as possible to prevent further production 
of amyloid deposits. 
Tafamidis meglumine 
Tafamidis stabilizes the mutant TTR tetramer by binding to the thyroxine binding sites, preventing its 
dissociation into monomers. For the treatment of TTR-FAP in adult patients with stage I symptomatic 
polyneuropathy, it is currently in clinical use in Europe in a single daily oral dose of 20 mg. Its efficacy has been 
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proven in both Val50Met and non-Val50Met TTR mutations. It is well tolerated and increases the quality of life. 
Its long-term efficacy is currently being assessed [1,3,6,10]. 
Diflunisal 
Diflunisal, a nonsteroidal anti-inflammatory drug, is currently not licensed for the treatment of stage I and stage 
II TTR-FAP. It prevents the dissociation, misfolding and misassembly of the mutated TTR tetramer. A single 
multicentre study of Berk et al. has shown that diflunisal inhibits polyneuropathy progression and increases 
quality of life  in TTR-FAP patients with various stages of disease. Gastrointestinal, cardiac and renal side 
effects may make its use problematic. Further investigations concerning its safety and effect will have to 
determine its potential use [6,11]. 
Liver transplantation 
Liver transplantation stops the production of the mutated TTR in the liver but not in the choroid plexus and 
retinal epithelium. Ocular, leptomeningeal and cerebral manifestations such as TIA-like episodes, stroke, aura-
like episodes and epileptic seizures are thus not influenced by liver transplantation [1,3,5,12,13]. Survival-rate 
post-liver transplantation is worse in non-Val50Met TTR-FAP: the five-year survival rate for non-
Val50MetTTR-FAP is 50-60% compared to 80-82% in Val50Met TTR-FAP [1,3,6,14].  
It has been reported that a longer preoperative disease course of FAP is a negative prognostic factor for liver 
transplantation. It should therefore be performed rather early than late. However, recent guidelines suggest to 
continue tafamidis therapy as first-line therapy, and keep liver transplantation in reserve until clinical 
progression under tafamidis occurs [1,5,6,15]. Side effects of transplantation and reports of negative neurological 
evolution despite liver transplant, as in our second patient, were also considered when formulating this guideline 
[16]. 
Contraindications for liver transplantation include: active and uncontrolled cancer; age >50 years for males and 
>70 years for females; modified body mass index below 800 kg g/L m²; some non-Val50Met TTR mutations; 
cardiac insufficiency. However, a combined heart and liver transplantation may be considered in selected cases 
[6]. Some mutations are known to frequently cause cardiac or combined cardiac and neurological involvement. 
The mutation in our third patient is very rare and causes combined cardiac and neuropathic disease. One other 
published case had combined involvement as well [17] . 
In case of domino liver transplantation, where a patient with a severe liver disease receives a liver from a FAP 
patient, the domino liver transplantation acceptor is at risk of developing FAP. Except for the production of 
mutated TTR, a normal liver function is required to qualify for domino transplantation. In half of the patients, 
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amyloid deposits were observed in labial salivary glands five years after domino liver transplantation. 
Nonetheless,  it is still done because of the shortage of donor livers  [3]. 
Therapies in development 
New therapies that are currently being developed include posttranscriptional gene silencing (using small 
interfering RNA (siRNA) or antisense oligonucleotides), immunotherapy using antibodies and a combination of 
doxycycline-tauroursodeoxycholic acid [3,6].  
The use of siRNA was shown to interfere with gene expression through RNA interference. Substantial and 
prolonged down-regulation of TTR protein level was observed following treatment with the siRNA ALN-TTR01 
and ALN-TTR02. The phase 3 APOLLO study with Patisiran (ALN-TTR02) that has recently been completed 
shows promising results concerning polyneuropathy symptoms, quality of life, exploratory cardiac measures, 
safety and tolerability (D. Adams, personal communication). Another phase 3 study involving ISIS 420915, an 
antisense oligonucleotide, is in its final stage [18]. Postponing liver transplantation until results of these studies 
are known should be considered [6]. Studies on clinical efficacy and safety of long-term TTR knockdown have 
not been performed yet. The decrease in retinol-binding protein levels due to TTR knockdown is a possible 
adverse effect. An advantage compared to liver transplantation is that the siRNA ALN-TTR02 knocks down 
both the mutant and wild-type TTR [18].  
Current treatment guidelines 
Tafamidis is used as first-line therapy in stage I FAP. Eligibility for liver transplantation should be checked in 
case of progression of the disease. Off-label use of diflunisal or inclusion in clinical trials should be considered 
in stage II FAP.  Figure 1 shows a treatment algorithm for TTR-FAP, developed by the European Network for 
TTR-FAP (ATTReuNET) [6]. 
Follow-up and prognosis 
Neurological, cardiac, renal and ocular examination should be done periodically in all TTR-FAP mutation 
carriers, whether symptomatic or asymptomatic. Neurological examination consists of sensory, motor and reflex 
evaluation, EMG, assessment of postural blood pressure and heart rate variability, and the presence of carpal 
tunnel syndrome. Cardiac screening involves performing an electrocardiogram and echocardiogram, and 
measurement of BNP or NT pro-BNP. Detection of clinical manifestations in TTR-FAP carriers confirms the 
diagnosis and should result in therapy (Fig. 1). Symptomatic treatment and psychological support should also 
take place  [1,8].  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
10 
 
Death resulting from progressive cardiac amyloidosis has also been reported post-liver transplantation. This is 
most probably due to cardiac wild-type TTR deposition. Thus, when considering liver transplantation, 
assessment of cardiac function and post-transplantation follow-up is of utmost importance. Following liver 
transplantation, patients with an early onset, Val50Met mutation and shortened duration of the disease have a 
better prognosis than patients with late onset, non-Val50Met mutation and prolonged duration of the disease [6]. 
Due to the local mutated TTR synthesis in the choroid plexus and retinal epithelium, the ocular and nervous 
system may deteriorate despite liver transplantation, resulting in, among others, chronic open-angle glaucoma 
and cerebral amyloid angiopathy. A significant increase of atrial fibrillation, a predictor of cerebrovascular 
events such as transient ischemic attacks, ischemic stroke, intracerebral hemorrhage and subarachnoid 
hemorrhage was observed in Val50Met FAP patients post-liver transplantation. Increased overall survival post-
liver transplantation enables TTR-FAP patients to develop intracerebral amyloid deposits which increases the 
risk of brain hemorrhage. Immunosuppressive treatment following transplantation may render the patient 
susceptible to infections [1,3,5,6,12,16]. 
Genetic counselling 
There is an urgent need for genetic counselling for patients and at-risk relatives [6]. Genetic counselling brings 
along several stressors for the patient and his or her relatives [1].  
As mentioned, making the diagnosis early may be of pivotal importance in patient outcome. However, genetic 
testing for TTR-FAP before the age of 18 should not be done since its practice holds no medical benefit. This 
may change in the future depending on the acquisition of new insights or therapies. Prenatal genetic testing and 
pre-implantation genetic diagnosis can be considered in some families [8,19] . 
In case of a positive genetic test, the gene carrier should not receive presymptomatic treatment since at this time 
it is not an accepted indication. The gene carrier should, however, be monitored regularly. Suspicion of 
symptom-onset matching with TTR-FAP should result in treatment [8]. 
 
Conclusion 
FAP is a heterogeneous disease with a variety of possible symptoms, depending on which tissue is affected. A 
multiplicity of mutations has been described, each with a diverse expression. It is a rare disorder with major 
influence on the daily life of patients. When possible, patients that cannot undergo liver transplantation or get 
tafamidis should be enrolled in clinical trials to test efficacy and safety of new treatment modalities. In an early 
stage, liver transplantation is a valid option when symptoms are progressive despite tafamidis therapy, although 
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it does not eliminate the production of wild-type TTR and TTR production from retinal cells and the choroid 
plexus. Liver transplantation and the associated immunosuppressive treatment itself holds several risks. 
Therefore, additional prospective clinical research is necessary to assess the course and outcome of these non-
Val50Met TTR mutations, especially in non-endemic regions. 
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Table 1 
Course and characteristics of early- and late-onset TTR-FAP. 
 Early-onset Val50Met TTR-FAP  Late-onset Val50Met TTR-FAP 
Age of onset 
 
<50 years >50 years 
Country 
 
Portugal, Japan, Brazil Sweden, France, UK, Italy, Japan 
Positive family history 
 
94% 48% 
Initial clinical presentation 
 
Peripheral neuropathy 
 
57% 81% 
Autonomic neuropathy 
 
48% 10% 
Mean delay for walking aid 
 
>5.6 years 3 years 
Cardiac 
 
Progressive conduction disorders Restrictive cardiomyopathy 
Heart failure 
Median survival 
 
11 years 7.3 years 
Causes of death 
 
Cachexia, infections Heart failure 
Sudden death 
Cachexia or secondary infection 
 
TTR-FAP transthyretin familial amyloid polyneuropathy. Modified from [3]. 
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Table 2  
Summary of cases of TTR-FAP. 
 Case one Case two Case three Case four 
Sex 
 
Male Male Male Male 
Year of birth 
 
1948 1972 1974 1945 
TTR mutation 
 
p.Val48Met p.Val52Ala p.Ala59Val p.Val50Met 
Symptom onset 
 
1998 2012 2014 2015 
Symptoms 
 
 
 
 
 
 
 
 
Sensorimotor and 
autonomic 
polyneuropathy 
Neuropathic pain 
Muscle wasting 
Impotence 
Hypotension 
Intestinal motility 
disturbance 
Sensory more than 
motor 
polyneuropathy 
Neuropathic pain 
Cachexia 
Impotence 
Hypotension 
Intestinal motility 
disturbance 
Symmetric 
sensorimotor 
polyneuropathy in 
lower limbs 
Neuropathic pain 
Impotence 
Weight loss 
Hypotension 
Intestinal motility 
disturbance 
Sensorimotor and 
autonomic 
polyneuropathy 
Neuropathic pain 
 
First diagnosis 
 
 
Chronic 
inflammatory 
demyelinating 
polyneuropathy 
TTR-FAP TTR-FAP with 
cardiac amyloidosis 
Chronic idiopathic 
axonal neuropathy 
Targeted 
treatment 
 
 
 
 
None Tafamidis 
Liver 
transplantation in 
2014 
Diflunisal 
Tafamidis 
 
Tafamidis 
 
Outcome Deceased in 2012 Deceased in 2016 Doing well on 
tafamidis therapy 
Stable on tafamidis 
therapy 
Peculiar findings Negative sural 
nerve, rectal and 
adipose biopsy for 
amyloidosis 
Negative evolution 
after liver 
transplantation 
Mild improvement 
on tafamidis 
None 
 
TTR-FAP transthyretin familial amyloid polyneuropathy. 
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Fig.1 Treatment algorithm for TTR-FAP 
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Legend 
Fig.1 Treatment algorithm for TTR-FAP 
Stage I: walking unaided outside. Stage II: walking with aid. Protocol for clinical trials for antisense 
oligonucleotides, small interfering RNA, combination doxycycline-tauroursodeoxycholic acid; or diflunisal off-
label. Modified from [6]. 
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Table 1 
Course and characteristics of early- and late-onset TTR-FAP. 
 Early-onset Val50Met TTR-FAP  Late-onset Val50Met TTR-FAP 
Age of onset 
 
<50 years >50 years 
Country 
 
Portugal, Japan, Brazil Sweden, France, UK, Italy, Japan 
Positive family history 
 
94% 48% 
Initial clinical presentation 
 
Peripheral neuropathy 
 
57% 81% 
Autonomic neuropathy 
 
48% 10% 
Mean delay for walking aid 
 
>5.6 years 3 years 
Cardiac 
 
Progressive conduction disorders Restrictive cardiomyopathy 
Heart failure 
Median survival 
 
11 years 7.3 years 
Causes of death 
 
Cachexia, infections Heart failure 
Sudden death 
Cachexia or secondary infection 
 
TTR-FAP transthyretin familial amyloid polyneuropathy. Modified from [3]. 
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Table 2  
Summary of cases of TTR-FAP. 
 Case one Case two Case three Case four 
Sex 
 
Male Male Male Male 
Year of birth 
 
1948 1972 1974 1945 
TTR mutation 
 
p.Val48Met p.Val52Ala p.Ala59Val p.Val50Met 
Symptom onset 
 
1998 2012 2014 2015 
Symptoms 
 
 
 
 
 
 
 
 
Sensorimotor and 
autonomic 
polyneuropathy 
Neuropathic pain 
Muscle wasting 
Impotence 
Hypotension 
Intestinal motility 
disturbance 
Sensory more than 
motor 
polyneuropathy 
Neuropathic pain 
Cachexia 
Impotence 
Hypotension 
Intestinal motility 
disturbance 
Symmetric 
sensorimotor 
polyneuropathy in 
lower limbs 
Neuropathic pain 
Impotence 
Weight loss 
Hypotension 
Intestinal motility 
disturbance 
Sensorimotor and 
autonomic 
polyneuropathy 
Neuropathic pain 
 
First diagnosis 
 
 
Chronic 
inflammatory 
demyelinating 
polyneuropathy 
TTR-FAP TTR-FAP with 
cardiac amyloidosis 
Chronic idiopathic 
axonal neuropathy 
Targeted 
treatment 
 
 
 
 
None Tafamidis 
Liver 
transplantation in 
2014 
Diflunisal 
Tafamidis 
 
Tafamidis 
 
Outcome Deceased in 2012 Deceased in 2016 Doing well on 
tafamidis therapy 
Stable on tafamidis 
therapy 
Peculiar findings Negative sural 
nerve, rectal and 
adipose biopsy for 
amyloidosis 
Negative evolution 
after liver 
transplantation 
Mild improvement 
on tafamidis 
None 
 
TTR-FAP transthyretin familial amyloid polyneuropathy. 
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